FY2025 EPS Estimates for Cytokinetics Cut by HC Wainwright

Cytokinetics, Incorporated (NASDAQ:CYTK) – Equities researchers at HC Wainwright dropped their FY2025 EPS estimates for Cytokinetics in a note issued to investors on Thursday, November 6th. HC Wainwright analyst J. Pantginis now forecasts that the biopharmaceutical company will post earnings per share of ($5.75) for the year, down from their previous estimate of ($5.71). HC Wainwright has a “Buy” rating and a $120.00 price target on the stock. The consensus estimate for Cytokinetics’ current full-year earnings is ($5.24) per share. HC Wainwright also issued estimates for Cytokinetics’ Q4 2025 earnings at ($1.72) EPS.

Cytokinetics (NASDAQ:CYTK) last posted its earnings results on Wednesday, November 5th. The biopharmaceutical company reported ($1.54) EPS for the quarter, topping the consensus estimate of ($1.59) by $0.05. The business had revenue of $1.94 million during the quarter, compared to the consensus estimate of $6.05 million. During the same period in the prior year, the firm earned ($1.36) earnings per share. The business’s revenue was up 318.1% on a year-over-year basis.

Several other research firms have also weighed in on CYTK. Royal Bank Of Canada raised their target price on Cytokinetics from $82.00 to $87.00 and gave the company an “outperform” rating in a report on Tuesday. Evercore ISI increased their price objective on Cytokinetics from $60.00 to $80.00 and gave the company an “outperform” rating in a report on Wednesday, September 3rd. Bank of America raised their price objective on Cytokinetics from $52.00 to $56.00 and gave the company a “neutral” rating in a research note on Thursday, October 2nd. B. Riley reaffirmed a “buy” rating and set a $90.00 target price (up previously from $80.00) on shares of Cytokinetics in a research report on Monday. Finally, Stifel Nicolaus increased their price target on Cytokinetics from $87.00 to $96.00 and gave the company a “buy” rating in a report on Tuesday, September 2nd. Thirteen investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $77.86.

Cytokinetics Trading Up 6.9%

CYTK stock opened at $66.50 on Monday. The firm has a market cap of $8.13 billion, a PE ratio of -13.04 and a beta of 0.58. Cytokinetics has a 1 year low of $29.31 and a 1 year high of $66.72. The company has a fifty day simple moving average of $56.14 and a 200 day simple moving average of $42.47.

Hedge Funds Weigh In On Cytokinetics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. TD Asset Management Inc raised its holdings in Cytokinetics by 23.4% in the 3rd quarter. TD Asset Management Inc now owns 671,780 shares of the biopharmaceutical company’s stock valued at $36,921,000 after acquiring an additional 127,488 shares in the last quarter. Dana Investment Advisors Inc. grew its holdings in shares of Cytokinetics by 4.9% during the 3rd quarter. Dana Investment Advisors Inc. now owns 17,413 shares of the biopharmaceutical company’s stock worth $957,000 after purchasing an additional 811 shares in the last quarter. Intrust Bank NA bought a new stake in shares of Cytokinetics during the third quarter valued at approximately $250,000. Monaco Asset Management SAM raised its stake in shares of Cytokinetics by 182.4% in the third quarter. Monaco Asset Management SAM now owns 120,000 shares of the biopharmaceutical company’s stock valued at $6,595,000 after purchasing an additional 77,500 shares in the last quarter. Finally, Skandinaviska Enskilda Banken AB publ lifted its position in Cytokinetics by 280.7% in the third quarter. Skandinaviska Enskilda Banken AB publ now owns 149,957 shares of the biopharmaceutical company’s stock worth $8,242,000 after purchasing an additional 110,568 shares during the period.

Insider Activity at Cytokinetics

In other news, Director Wendell Wierenga sold 4,375 shares of the business’s stock in a transaction dated Monday, October 27th. The shares were sold at an average price of $58.68, for a total transaction of $256,725.00. Following the transaction, the director owned 32,444 shares in the company, valued at approximately $1,903,813.92. The trade was a 11.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Edward M. Md Kaye sold 6,757 shares of the company’s stock in a transaction dated Monday, October 6th. The shares were sold at an average price of $60.00, for a total transaction of $405,420.00. Following the transaction, the director directly owned 9,778 shares of the company’s stock, valued at $586,680. This represents a 40.86% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 56,983 shares of company stock valued at $3,165,356 in the last 90 days. 2.70% of the stock is owned by company insiders.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.